OR WAIT null SECS
September 10, 2021
Avantor has acquired the Masterflex bioprocessing business and related assets of Antylia Scientific.
The White House announced a nearly $3 billion program to ramp up production of vaccines and their components.
September 09, 2021
Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.
Ardena acquires Idifarma, adding spray drying technology and high potency capabilities.
The orphan drug designation for TCR² Therapeutics’ Gavo-cel will facilitate research into a treatment for cholangiocarcinoma.
AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the advance purchase agreement for the delivery of Vaxzevria.
The Coalition for Epidemic Preparedness Innovations stated that developing the next generation of COVID-19 vaccines will only be possible if comparator vaccines are available for clinical trials.
Moderna’s new single-dose vaccine will be a booster for both COVID-19 and the flu.
FDA placed a clinical hold on the BMN 307 Phearless Phase I/II study, which was evaluating an investigational PAH gene therapy in adults with PKU.
Thermo Fisher Scientific plans to expand its Nashville, Tenn., site by establishing a dedicated single-use technology manufacturing facility at the site, doubling capacity.